March 21, 2014Journal of Cardiovascular Pharmacology and Therapeutics
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes
Key result
Rivaroxaban was noninferior to warfarin for stroke prevention in atrial fibrillation, with a 33% lower incidence of intracranial hemorrhage, and reduced cardiovascular events in acute coronary syndrome.
Why the study?
Does rivaroxaban prevent stroke/systemic embolism in atrial fibrillation and reduce cardiovascular events in acute coronary syndromes compared to standard therapies?
Population
Patients with nonvalvular atrial fibrillation and patients with recent acute coronary syndromes
Comparison
Rivaroxaban vs Warfarin (for atrial fibrillation)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support rivaroxaban consideration in AF; leaves open dedicated ACS trials before practice change.
Structured PICO
Does rivaroxaban prevent stroke/systemic embolism in atrial fibrillation and reduce cardiovascular events in acute coronary syndromes compared to standard therapies?
P
Population
Patients with nonvalvular atrial fibrillation and patients with recent acute coronary syndromes
I
Intervention
Rivaroxaban
C
Comparator
Warfarin (for atrial fibrillation)
O
Outcome
Stroke/systemic embolism (for atrial fibrillation); composite of death from cardiovascular causes, myocardial infarction, and stroke (for acute coronary syndromes)composite
Rivaroxaban is a valuable alternative to warfarin for stroke prevention in atrial fibrillation and shows potential for reducing cardiovascular events in acute coronary syndromes, though bleeding risks require caution.
Limitations
- Lack of an antidote
- Absence of a widely available method to reliably monitor the anticoagulant effect
- Adequacy of warfarin management and the increase in event rate at the end of the ROCKET-AF trial
- Limited experience in combination with novel oral antiplatelet agents
- Concerns about the adequacy of warfarin management in the ROCKET-AF trial
- Increase in event rate at the end of the ROCKET-AF trial
Cite This Study
Reddy et al. (2014) conducted a review in Atrial fibrillation and acute coronary syndromes. Rivaroxaban vs. Warfarin was evaluated. Rivaroxaban was noninferior to warfarin for stroke prevention in atrial fibrillation, with a 33% lower incidence of intracranial hemorrhage, and reduced cardiovascular events in acute coronary syndrome.